In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogenerics Are Coming and They're Not the Generics We Know

Executive Summary

Biotech and would-be biogenerics companies are battling to shape the future of generic biologics. The FDA, along with established biotech and drug companies, has opposed the concept of biogenerics, insisting the compounds are too complex to be reproducible in a reliable fashion. Challengers insist that the science is advanced enough to make such products feasible and are pumping significant time and money into bringing them to market.
Advertisement

Related Content

Big Pharma May Be Big Player in Follow-On Biologics Market
FDA Hesitates on Biogenerics
FDA Faces Mounting Pressure on Shortcut Approval Pathway
An FDA Nominee, Biologics Reviews Move to CDER
A Precarious Union: Combining Proprietary and Generic Businesses
TKT: Bloodied But Unbowed
TKT Genericizes Proteins
TKT Genericizes Proteins
Generic Update: Brand-Name Companies Vs. Independents
Can Human Growth Hormone Be Genericized?

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV001802

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel